MARKET

MNKD

MNKD

Mannkind
NASDAQ
3.090
+0.100
+3.34%
After Hours: 3.110 +0.02 +0.65% 19:13 09/30 EDT
OPEN
3.000
PREV CLOSE
2.990
HIGH
3.220
LOW
3.000
VOLUME
4.28M
TURNOVER
0
52 WEEK HIGH
5.44
52 WEEK LOW
2.490
MARKET CAP
795.18M
P/E (TTM)
-8.9023
1D
5D
1M
3M
1Y
5Y
When Can We Expect A Profit From MannKind Corporation (NASDAQ:MNKD)?
With the business potentially at an important milestone, we thought we'd take a closer look at MannKind Corporation's...
Simply Wall St. · 3d ago
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung d...
GlobeNewswire · 09/21 21:00
A number of insiders bought MannKind Corporation (NASDAQ:MNKD) stock last year, which is great news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 09/08 17:18
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.
Benzinga · 09/06 14:15
Hot Stocks: HUT gains on Bitcoin production, CSGP pops on S&P entry, MNKD rises, and BBBY falls 15%
Hut 8 Mining Corp. (NASDAQ:HUT) tracked higher during Tuesday’s prema...
Seekingalpha · 09/06 12:24
BRIEF-MannKind Successfully Completes Phase 1 Study Of Inhaled Clofazimine
BRIEF-MannKind Successfully Completes Phase 1 Study Of Inhaled Clofazimine
Reuters · 09/06 11:27
Mannkind to further advance lung disease candidate after positive Phase 1 data
MannKind Corporation (NASDAQ:MNKD), a biotech focused on rar...
Seekingalpha · 09/06 10:39
Mannkind Completes Phase 1 Study of Inhaled Clofazimine; Says 'Study supports the dosing regimen that will be pursued in further clinical programs'
  Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical
Benzinga · 09/06 10:15
More
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.